Abstract:The identification and characterization of tumor antigens are central objectives in developing anti-cancer immunotherapy. Traditionally, tumor-associated antigens (TAAs) are considered relatively restricted to tumor cells (i.e., overexpressed proteins in tumor cells), whereas tumor-specific antigens (TSAs) are considered unique to tumor cells. Recent studies have focused on identifying patient-specific neoantigens, which might be highly immunogenic because they are not expressed in normal tissues. The opposite strategy has emerged with the discovery of anti-regulatory T cells (anti-Tregs) that recognize and attack many cell types in the tumor microenvironment, such as regulatory immune cells, in addition to tumor cells. The term proposed in this review is "tumor microenvironment antigens" (TMAs) to describe the antigens that draw this attack. As therapeutic targets, TMAs offer several advantages that differentiate them from more traditional tumor antigens. Targeting TMAs leads not only to a direct attack on tumor cells but also to modulation of the tumor microenvironment, rendering it immunocompetent and tumor-hostile. Of note, in contrast to TAAs and TSAs, TMAs also are expressed in non-transformed cells with consistent human leukocyte antigen (HLA) expression. Inflammation often induces HLA expression in malignant cells, so that targeting TMAs could additionally affect tumors with no or very low levels of surface HLA expression. This review defines the characteristics, differences, and advantages of TMAs compared with traditional tumor antigens and discusses the use of these antigens in immune modulatory vaccines as an attractive approach to immunotherapy. Different TMAs are expressed by different cells and could be combined in anti-cancer immunotherapies to attack tumor cells directly and modulate local immune cells to create a tumor-hostile microenvironment and inhibit tumor angiogenesis. Immune modulatory vaccines offer an approach for combinatorial therapy with additional immunotherapy including checkpoint blockade, cellular therapy, or traditional cancer vaccines. These combinations would increase the number of patients who can benefit from such therapeutic measures, which all have optimal efficiency in inflamed tumors.

Antigen-specific agents in development.

Therapeutic Antibodies and Immunologic Conjugates

Undefined-antigen vaccines.

Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines

Building better monoclonal antibody-based therapeutics

Human Tumor Antigens and Cancer Immunotherapy

Challenges in Antibody Development against Tn and Sialyl-Tn Antigens

Landscape of Tumor Antigens in T Cell Immunotherapy

Antigen-specific T cell immunotherapy by in vivo mRNA delivery

Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects

Tumor microenvironment antigens

Predicting genes involved in human cancer using network contextual information.

Design of antigens to present a tumor-specific cryptic epitope

Nano-engineered monoclonal antibodies expanding the newer avenues for cancer targeting

Cancer vaccines: the next immunotherapy frontier

Relapse of idiopathic pulmonary haemorrhage and glomerulonephritis associated with cytomegalovirus (CMV) infection.

The landscape of T cell antigens for cancer immunotherapy

Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process

The recognition and treatment of congenital heart disease. I. Differential diagnosis of congenital heart disease.

Turning the corner on therapeutic cancer vaccines

Tumor Antigens beyond the Human Exome